Publish Date: May 2019 | Category: Healthcare, Pharmaceuticals & Medical Devices | Publisher: BCC Research | Status: Publish
The global market for antihypertensive drugs should grow from nearly $26.3 billion in 2018 to $27.8 billion by 2023 with a compound annual growth rate (CAGR) of 1.1% for the period of 2018-2023.
The current report offers a detailed analysis of the antihypertensive drug market. The study includes a discussion of antihypertensive drugs prescribed for lowering the high blood pressure and for the treatment of pulmonary arterial hypertension (PAH). The report excludes drugs used in the treatment of ocular hypertension. The market size includes both branded and generic drugs.
The report highlights the current and future market potential of antihypertensive drugs and provides a detailed analysis of the competitive environment, regulatory scenario, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market shares for key market players.
The report details market shares of antihypertensive drugs based on drug class and geography. Based on drug class, the market is segmented into ACE inhibitors (angiotensin-converting enzyme inhibitors), ARBs (angiotensin II receptor blockers), beta blockers, calcium channel blockers, diuretics, combination drugs, and others (a segment that includes direct renin inhibitors, alpha blockers, PDE-5 inhibitors, stimulators of soluble guanylate cyclase, endothelin receptor antagonists, vasodilators, and prostacyclin receptors).
The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Spain, Italy, Japan, China and India. For market estimates, data is provided for 2017 as the base year, with forecasts for 2018 through 2023. Estimated values are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
- 67 tables - Country specific data and analysis for France, Germany, Italy, U.K., Spain, Russia, India, China, Japan, United States, Canada, Middle East and Africa - A brief study of current and future market potential of antihypertensive drugs along with a detailed analysis of the competitive environment - Exposure to the industry driven underlying markets, government regulations, and technology updates - Coverage of regulatory dynamics, pipeline analysis, patent analysis, and market drivers, restrains, and opportunities - Company profiles of major manufacturers, suppliers, and supply chain participants, including Allergan Plc, Boehringer Ingelheim GMBH, Johnson & Johnson, Daiichi Sankyo Co. Ltd, Pfizer Inc. and Novartis AG
Table of Contents
Chapter 1 Introduction Study Goals and Objectives Reasons for Doing This Study Scope of Report Information Sources Methodology Geographic Breakdown Analysts’ Credentials BCC Custom Research Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background Hypertension Pathophysiology and Pathogenesis Classification Prevalence of Hypertension Antihypertensive Drugs Commonly Prescribed Antihypertensive Drugs Side Effects of Antihypertensive Drugs Contraindications of Major Antihypertensive Drugs Resistant Hypertension
Chapter 4 Market Dynamics Growth Drivers Increasing Prevalence of Hypertension Rising Geriatric Population and Government Assistance for Prescription Drugs Sedentary Lifestyle: Contributing Significantly toward High Risk of Hypertension Improved Awareness of Hypertension: Earlier Diagnosis and Treatment Market Restraints Patent Expirations of Branded Drugs Drug Development Process: High Cost and Pricing Pressures Market Opportunities Patent Expiration: Growth Opportunities for Generic Players Unmet Needs in Low- and Middle-Income Countries
Chapter 5 Market Breakdown by Drug Class Global Antihypertensive Drug Market Angiotensin-Converting Enzyme (ACE) Inhibitors Market Size and Forecast Market Analysis Angiotensin II Receptor Blockers Market Size and Forecast Market Analysis Beta Blockers Market Size and Forecast Market Analysis Calcium Channel Blockers Market Size and Forecast Market Analysis Diuretics Market Size and Forecast Market Analysis Combination Drug Market Size and Forecast Market Analysis Others Market Size and Forecast Market Analysis
Chapter 6 Market Breakdown by Region Global Market for Antihypertensives by Region North America United States Canada Mexico Europe Germany France U.K. Italy Spain Rest of Europe Asia-Pacific Japan China India Rest of Asia-Pacific South America Market Size and Forecast Market Analysis Middle East and Africa Market Size and Forecast Market Analysis
Chapter 7 Regulatory Environment Regulations in the U.S. New Drug Approvals The FDA Modernization Act of 1997 Fast-Track Status Special Protocol Assessments Medicare Principles for Clinical Evaluation of New Antihypertensive Drugs Hypertension Guidelines in the U.S. Regulations in Europe Hypertension Guidelines in Europe Pricing and Reimbursement Regulations in Asia-Pacific Regulations in Japan Regulations in China Regulations in India
Chapter 8 Patent Analysis Patent Length and Market Exclusivity
Chapter 9 Pipeline Analysis Overview of the Drug Development Process Pipeline Analysis of Antihypertensive Drugs Antihypertensive Drugs in Phase I Clinical Trials Antihypertensive Drugs in Phase II Clinical Trials Antihypertensive Drugs in Phase III Clinical Trials Late-Stage Pipeline Drugs
Chapter 10 Competitive Landscape Global Company Share Analysis Mergers and Acquisitions Agreements, Collaborations, and Partnerships Impact of Generic Antihypertensives on the Market
Chapter 11 Company Profiles ALLERGAN PLC Company Overview Business Performance Products Offered Developments and Strategies ASTELLAS PHARMA INC. Company Overview Products Offered Developments and Strategies ARBOR PHARMACEUTICALS LLC Company Overview Products Offered ASTRAZENECA PLC Company Overview Business Performance AstraZeneca plc Business Segment Revenue AstraZeneca Plc Revenue by Region Segment Product Portfolio Developments and Strategies BAYER AG Company Overview Business Performance Products Offered Developments and Strategies BOEHRINGER INGELHEIM GMBH Company Overview Business Performance Products Offered Developments and Strategies DAIICHI SANKYO CO. LTD. Company Overview Business Performance Products Offered Developments and Strategies ELI LILLY AND CO. Company Overview Products Offered Developments and Strategies GILEAD SCIENCES INC. Company Overview Business Performance Products Offered Developments and Strategies GLAXOSMITHKLINE PLC Company Overview Products Offered Developments and Strategies HIKMA PHARMACEUTICALS PLC Company Overview Products Offered JOHNSON & JOHNSON Company Overview Business Performance Product Portfolio Developments and Strategies LUPIN LTD. Company Overview Product Portfolio MERCK & CO. INC. Company Overview Products Offered Developments and Strategies NOVARTIS AG Company Overview Business Performance Products Offered Developments and Strategies PFIZER INC. Company Overview Business Performance Products Offered Developments and Strategies SANOFI Company Overview Business Performance Products Offered Developments and Strategies TAKEDA PHARMACEUTICAL CO. LTD. Company Overview Product Portfolio TEVA PHARMACEUTICAL INDUSTRIES LTD. Company Overview Products Offered UNITED THERAPEUTICS CORP. Company Overview Business Performance Products Offered Developments and Strategies